Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial.
Saved in:
| Title: | Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial. |
|---|---|
| Authors: | Zhao, Xiao1 (AUTHOR), Zhang, Jing1 (AUTHOR), Qiu, Lupeng1 (AUTHOR), Han, Quanli1 (AUTHOR), Yan, Xiang1 (AUTHOR), Zhu, Yanyun1 (AUTHOR), Wang, Jinliang1 (AUTHOR), Zhang, Xiaoling1 (AUTHOR), Jiao, Shunchang1 (AUTHOR) jiaosc@vip.sina.com, Sun, Shengjie1 (AUTHOR) ssjdoctor@163.com |
| Source: | BMC Medicine. 10/6/2025, Vol. 23 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
